Investors sent shares in Xenon Pharmaceuticals (NASDAQ:XENE) higher after the clinical stage biopharmaceutical group presented rosy results from a drug trial for the treatment of epilepsy.
Xenon today presented positive interim data for its ongoing phase one clinical trial, which is analyzing the impact of XEN1101, a Kv7 potassium channel opener, for the treatment of a variety of epileptic seizures at the 14th Eilat conference on new antiepileptic drugs and devices in Madrid.
In morning trade, Xenon Pharmaceuticals rose 7.5% to US$6.45.
The study was designed to assess XEN1101’s ability to curb so-called cortical excitability which arises with seizures and is an important consequence of traditional anti-epileptic drugs.
The initial findings suggest that XEN1101 demonstrates a number of significant benefits when compared to ezogabine, an older potassium channel modulator. First among them is that someone with epilepsy only has to take the XEN1101 pill once a day versus ezogabine’s three daily doses.
“From a safety perspective, the majority of adverse events were mild and resolved spontaneously, with an overall profile showing XEN1101 as safe and well tolerated,” said Dr. Simon Pimstone, Xenon’s chief executive. “When compared with the historical data generated with ezogabine, XEN1101 had approximately twice the effect at significantly lower doses.”